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BACKGROUND AND PURPOSE
Zileuton is the only 5-lipoxygenase (5-LOX) inhibitor marketed as a treatment for asthma, and is often utilized as a selective
tool to evaluate the role of 5-LOX and leukotrienes. The aim of this study was to investigate the effect of zileuton on
prostaglandin (PG) production in vitro and in vivo.
EXPERIMENTAL APPROACH
Peritoneal macrophages activated with lipopolysaccharide (LPS)/interferon g (LPS/IFNg), J774 macrophages and human whole
blood stimulated with LPS were used as in vitro models and rat carrageenan-induced pleurisy as an in vivo model.
KEY RESULTS
Zileuton suppressed PG biosynthesis by interference with arachidonic acid (AA) release in macrophages. We found that
zileuton significantly reduced PGE2 and 6-keto prostaglandin F1a (PGF1a) levels in activated mouse peritoneal macrophages
and in J774 macrophages. This effect was not related to 5-LOX inhibition, because it was also observed in macrophages from
5-LOX knockout mice. Notably, zileuton inhibited PGE2 production in LPS-stimulated human whole blood and suppressed
PGE2 and 6-keto PGF1a pleural levels in rat carrageenan-induced pleurisy. Interestingly, zileuton failed to inhibit the activity of
microsomal PGE2 synthase1 and of cyclooxygenase (COX)-2 and did not affect COX-2 expression. However, zileuton
significantly decreased AA release in macrophages accompanied by inhibition of phospholipase A2 translocation to cellular
membranes.
CONCLUSIONS AND IMPLICATION
Zileuton inhibited PG production by interfering at the level of AA release. Its mechanism of action, as well as its use as a
pharmacological tool, in experimental models of inflammation should be reassessed.
Abbreviations
5-LOX, 5-lipoxygenase; AA, arachidonic acid; COX, cyclooxygenase; cPLA2, cytosolic phospholipase A2; cysLTs, cysteinyl
leukotrienes; DMEM, Dulbecco’s modified Eagle’s medium; EIA, enzyme immunoassay; FBS, fetal bovine serum; GSH,
glutathione; IFNg, interferon g; KO, knockout; LPS, lipopolysaccharide; MLVs, multilamellar vesicles; mPGES1,
microsomal prostaglandin E2 synthase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; OD, optical
density; PG, prostaglandin; RIA, radioimmunoassay; WT, wild type
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Introduction
Zileuton, a benzothiophene N-hydroxyurea, is the
only approved inhibitor of 5-lipoxygenase (5-LOX,
EC number 1.13.11.34; nomenclature follows Alex-
ander et al., 2009) and is thought to intervene with
allergic and inflammatory diseases by suppression of
leukotriene (LT) biosynthesis (Peters-Golden and
Henderson, 2007). The compound belongs to the
class of iron ligand-type inhibitors of 5-LOX that
not only chelates the active site iron of the enzyme
but also possesses weak-reducing properties (Carter
et al., 1991). Given the important role that LTs play
in airway inflammation, zileuton provides an addi-
tional therapeutic option in the management of
chronic and persistent asthma. In fact, zileuton was
the first and only 5-LOX inhibitor that entered the
US market in 1997 as a new type of drug for the
prophylaxis and chronic treatment of asthma
(Drazen et al., 1999). However, zileuton exhibits
liver toxicity, and thus, its clinical use is limited by
the need to monitor hepatic enzyme levels. Inter-
estingly, the hepatic injury caused by zileuton
appears to be a direct toxic effect that is unrelated to
the inhibition of 5-LOX (Beierschmitt et al., 2001).
In addition, zileuton is often utilized as a tool to
evaluate the role of 5-LOX and LTs in in vitro as well
as in in vivo models of inflammation. In fact, it has
shown beneficial effects in a number of pathological
conditions in animals, including inflammation of
the upper airway, dermatological diseases, chronic
obstructive pulmonary disease (Berger et al., 2007),
spinal cord injury (Genovese et al., 2008), colitis
(Cuzzocrea et al., 2005), multiple organ injury and
dysfunction caused by endotoxemia (Collin et al.,
2004), liver metastases (Gregor et al., 2005) and oral
carcinogenesis (Li et al., 2005). Generally, the ben-
eficial effects of zileuton in these disorders are attrib-
uted to the inhibition of 5-LOX and consequently to
a reduced formation of LTs.
It has long been proposed that the inhibition of
the cyclooxygenase (COX, EC number 1.14.99.1)
pathway could enhance LT generation by increasing
the substrate supply for 5-LOX (Hamad et al., 2004).
However, this so-called ‘arachidonate shunt’
hypothesis should be viewed with care because
there is some evidence that COX and 5-LOX utilize
distinct arachidonate pools (Peters-Golden and
Brock, 2000), which would preclude this mecha-
nism. On the contrary, little information is available
on prostaglandin (PG) generation when the 5-LOX
pathway is inhibited, although in some reports, a
concomitant decrease of PG production has been
observed in the presence of the 5-LOX inhibitor
zileuton (Carter et al., 1991; Chen et al., 2004;
Gregor et al., 2005), and more recently, an opposite
effect of the compound has been observed in cardi-
omyocytes (Kwak et al., 2010). Moreover, we have
recently demonstrated that genetic [5-LOX gene
knockout (KO)] or pharmacological inhibition of
5-LOX by zileuton in murine peritoneal macroph-
ages activated with lipopolysaccharide/interferon g
(LPS/IFNg) led to a significant decrease in the pro-
duction of PGs (Rossi et al., 2005). Interestingly,
inhibition of PG (i.e. PGE2 and 6-keto PGF1a) pro-
duction induced by zileuton was greater than that
observed as a consequence of 5-LOX-gene deletion.
Therefore, it is reasonable to speculate that other
mechanisms than 5-LOX inhibition might contrib-
ute to the anti-inflammatory effects of zileuton.
Here, we show that in addition to LT production,
zileuton suppressed PG biosynthesis in in vitro
models (peritoneal macrophages activated with LPS/
IFNg or zymosan, J774 cells and human whole blood
activated with LPS) as well as in rat carrageenan-
induced pleurisy. Moreover, our results demon-
strated that zileuton inhibited PG production by
interfering at the level of arachidonic acid (AA)
release.
Methods
Animals
All animal care and experimental procedures were
in compliance with Italian regulations on protec-
tion of animals used for experimental and other
scientific purpose (Ministerial Decree 116192) as
well as with the European Economic Community
regulations (Official Journal of E.C. L 358/1 12/18/
1986). CD1 mice (25–30 g, Harlan, Milan, Italy),
mice with a targeted disruption of the 5-LOX gene
(5-LOX KO) (Jackson Laboratories; Harlan, Italy),
and Wistar Han rats (200–220 g, Harlan, Milan,
Italy) were housed in a controlled environment and
provided ad libitum with standard rodent chow and
water.
Peritoneal macrophages
Peritoneal macrophages were elicited by intraperito-
neal (i.p.) injection of 4% sterile thioglycollate
medium (2 mL). After 3 days, mice were killed with
carbon dioxide, and macrophages were harvested as
described (Nunoshiba et al., 1993). The peritoneal
macrophages were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 2 mM
glutamine, 25 mM HEPES, 100 U·mL-1 penicillin,
100 mg·mL-1 streptomycin, 10% fetal bovine serum
(FBS) and 1.2% sodium pyruvate. Cells were plated
in 24-well culture plates at a density of 5 ¥ 105
cells·mL-1 or in 60 mm-diameter culture dishes (3 ¥
106 cells3·mL-1 dish) and allowed to adhere at 37°C
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in 5% CO2 for 3 h, and then non-adherent cells were
removed by washing with sterile phosphate-
buffered saline (PBS). Immediately before the experi-
ments, the culture medium was replaced by fresh
medium without FBS in order to avoid interference
with the radioimmunoassay (RIA).
The peritoneal macrophages were treated with
Escherichia coli LPS (Serotype 0111:B4, 10 mg·mL-1)
plus IFNg (100 U·mL-1) for 24 h or zymosan (20–30
particles·cell-1) for 60 min. Incubation media were
assayed for prostanoids (PGE2 and 6-keto PGF1a) and
cysteinyl leukotrienes (cysLTs) by RIA and enzyme
immunoassay (EIA), respectively. The levels of
eicosanoids are expressed as ng·mL-1. Cells were
used for Western blot analysis.
Mitochondrial respiration
Cell respiration was assessed by the mitochondria-
dependent reduction of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) to
formazan (Mosmann, 1983). After stimulation with
LPS (10 mg·mL-1) and IFNg (100 U·mL-1) in the
absence or presence of zileuton (1–10–100 mM) for
24 h, cells were incubated with MTT (0.2 mg·mL-1)
in 96-well plates for 1 h. Culture medium was
removed by aspiration and the cells were solubilized
in dimethyl sulfoxide (DMSO) (0.1 mL). The extent
of cellular reduction of MTT to formazan was quan-
tified by the measurement of optical density (OD) at
550 nm.
J774 macrophages
The murine monocyte/macrophage J774 cell line
was grown in DMEM supplemented with 2 mM
glutamine, 25 mM HEPES, 100 U·mL-1 penicillin,
100 mg·mL-1 streptomycin, 10% FBS and 1.2%
sodium pyruvate. Cells were plated in 24-well
culture plates at a density of 2.5 ¥ 105 cells·mL-1 or in
60 mm-diameter culture dishes (3 ¥ 106 cells per
3 mL dish) and allowed to adhere at 37°C in 5% CO2
for 2 h. Immediately before the experiments, culture
medium was replaced by fresh medium without FBS
and cells were stimulated as described.
Activation of COX-2 in J774 macrophages
Cells were stimulated with LPS (10 mg·mL-1) for 24 h
(Sautebin et al., 1999) in the absence or presence of
zileuton (1 to 100 mM). In other experiments, after
cell stimulation (LPS 10 mg·mL-1 for 24 h), the super-
natant was replaced with fresh medium containing
vehicle or zileuton (100 mM) and incubated for
15 min before the addition of AA (3–15 mM) for
30 min. The measurement of PGE2 and 6-keto PGF1a
in the cell supernatants was performed by RIA,
whereas the cells were used for Western blot studies.
Human whole blood assay
Peripheral blood from healthy adult volunteers,
who had not received any medication for at least 2
weeks under informed consent, was obtained by
venepuncture and collected in syringes containing
heparin (10 U·mL-1). To evaluate PG production in
whole blood, 1 mL aliquots of human blood
samples were incubated, in the presence or absence
of zileuton (1, 3.3, 10, 33 and 100 mM) with LPS
(10 mg·mL-1) or saline (control) for 24 h at 37°C as
previously described (Tacconelli et al., 2002). PGE2
plasma levels were measured by RIA.
Carrageenan-induced pleurisy in rats
Zileuton (10 mg·kg-1), MK-886 (1.5 mg·kg-1) or
indomethacin (5 mg·kg-1) were given i.p. 30 min
before carrageenan. A group of rats received the
vehicle (DMSO, 4%, i.p.) 30 min before carrag-
eenan. Rats were anaesthetized with enflurane 4%
mixed with O2, 0.5 L·min-1, N2O 0.5 L·min-1 and
submitted to a skin incision at the level of the left
sixth intercostal space. The underlying muscle was
dissected, and saline (0.2 mL) or l-carrageenan type
IV 1% (w·v-1) (0.2 mL) was injected into the pleural
cavity. The skin incision was closed with a suture,
and the animals were allowed to recover. At 4 h after
the injection of carrageenan, the animals were killed
by inhalation of CO2. The chest was carefully
opened, and the pleural cavity was rinsed with 2 mL
saline solution containing heparin (5 U·mL-1). The
exudate and washing solution were removed by
aspiration, and the total volume was measured. Any
exudate that was contaminated with blood was dis-
carded. The amount of exudate was calculated by
subtracting the volume injected (2 mL) from the
total volume recovered. Leukocytes in the exudate
were resuspended in PBS and counted with a light
microscope in a Burker’s chamber after vital trypan
blue staining.
The amounts of PGE2, 6-keto PGF1a and leukot-
riene B4 (LTB4) in the supernatant of centrifuged
exudate (800¥ g for 10 min) were assayed by RIA
(PGE2) and EIA (6-keto PGF1a and LTB4) according
to the manufacturer’s protocol, respectively. The
results are expressed as ng per rat and represent the
mean  standard error (SE) of 14 rats.
Determination of PGE2 synthase activity in
A549 microsomes
Preparation of microsomes of A549 cells and deter-
mination of microsomal prostaglandin E2 synthase
(mPGES1) activity was performed as described
(Jakobsson et al., 1999; Thorén and Jakobsson,
2000). In brief, cells (2 ¥ 106 cells in 20 mL medium)
BJPEffect of zileuton on prostaglandin biosynthesis
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were plated in 175 cm2 flasks and incubated for 16 h
at 37°C and 5% CO2. Subsequently, the cell culture
medium was exchanged against DMEM high
glucose (4.5 g·L-1) medium containing 2% fetal calf
serum. In order to induce expression of mPGES1,
interleukin-1b (IL-1b) (1 ng·mL-1) was added and
cells were incubated for another 72 h. Thereafter,
cells were detached with trypsin/EDTA, washed with
PBS and frozen in liquid nitrogen. Ice-cold homog-
enization buffer [0.1 M potassium phosphate buffer
pH 7.4, 1 mM phenylmethanesulfonyl fluoride,
60 mg·mL-1 soybean trypsin inhibitor, 1 mg·mL-1 leu-
peptin, 2.5 mM glutathione (GSH) and 250 mM
sucrose] was added, and after 15 min at room tem-
perature, cells were resuspended and sonicated on
ice (3 ¥ 20 s). The homogenate was subjected to
differential centrifugation at 10 000¥ g for 10 min
and 174 000¥ g for 1 h at 4°C. The pellet (microso-
mal fraction) was resuspended in 1 mL homogeni-
zation buffer and total protein concentration was
determined by the Coomassie protein assay (Brad-
ford, 1976). Microsomal membranes were diluted in
PBS (0.1 M, pH 7.4) containing 2.5 mM GSH. The
reaction (100 mL total volume) was initiated by addi-
tion of PGH2 (20 mM, final concentration). After
1 min at 4°C, the reaction was terminated with
100 mL of stop solution (40 mM FeCl2, 80 mM citric
acid and 10 mM of 11b-PGE2). PGE2 was separated by
solid phase extraction using acetonitrile (200 mL)
and analysed by RP-HPLC [30% acetonitrile aq. +
0.007% trifluoroacetic acid (v·v-1), Nova-Pak® C18
column, 5 ¥ 100 mm, 4 mm particle size, flow rate
1 mL·min-1] with ultraviolet (UV) detection at
195 nm. 11b-PGE2 was used as internal standard to
quantify PGE2 product formation by integration of
the area under the peaks.
Activity assay of isolated COX-2
The effect of zileuton on the activity of isolated
human COX-2 was investigated as described
(Siemoneit et al., 2008). Briefly, purified COX-2
(human recombinant, 20 units; Cayman Chemical,
Ann Arbor, MI, USA) was diluted in 1 mL reaction
mixture containing 100 mM Tris buffer pH 8,
5 mM GSH, 5 mM haemoglobin and 100 mM
EDTA at 4°C, and pre-incubated with the test com-
pounds for 5 min. Samples were pre-warmed for
60 s at 37°C and AA (2 mM) was added to start the
reaction. After 5 min at 37°C, 12(S)-hydroxy-5-cis-
8,10-trans-heptadecatrienoic acid was extracted and
then analysed by HPLC [76% MeOH aq + 0.007%
trifluoroacetic acid (v·v-1), Nova-Pak® C18 column,
5 ¥ 100 mm, 4 mm particle size, flow rate
1 mL·min-1] with UV detection at 235 nm.
[3H]-AA labelling
J774 cells or elicited peritoneal macrophages were
labelled with 0.5 mCi·mL-1 and 0.1 mCi·mL-1
[5,6,8,9,11,12,14,15-3H(N)]AA (180–240 Ci·mmol-1),
respectively, overnight at 37°C in DMEM containing
10% FBS. After labelling, the cells were washed three
times with PBS containing 2 mg·mL-1 fatty acid-free
BSA. Thereafter, J774 macrophages were stimulated
for 24 h with LPS (10 mg·mL-1) and peritoneal mac-
rophages for 60 min with Ca2+-ionophore A23187
(1 mM) or zymosan (20–30 particles·cell-1) in the
absence or presence of zileuton (1–10–100 mM)
(Gijón et al., 2000). After incubation, the culture
medium was collected and centrifuged for 10 min at
10 000¥ g, and the cells were scraped into 0.5 mL of
0.1% triton X-100. The amount of radioactivity in
the cells and in the culture media was measured
by liquid scintillation counting (Tri-Carb 1500,
Packard, Milan, Italy). Background release from
unstimulated cells was subtracted from each
experimental point.
Determination of cell-free activity of human
recombinant cytosolic phospholipase A2
The cytosolic phospholipase A2 (cPLA2) coding
sequence was cloned from pVL1393 plasmid (kindly
provided by Dr Wonhwa Cho, University of Illinois
at Chicago) into pFastBacTM HT A containing a 6¥
His-tag coding sequence. The recombinant plasmid
was transformed into DH10Bac™ E. coli. Sf9 cells
were transfected with recombinant bacmid DNA
using Cellfectin® Reagent and the generated bacu-
lovirus was amplified. Overexpression of His-tagged
cPLA2 in baculovirus-infected Sf9 cells and isolation
using Ni-NTA agarose beads was performed as
described (de Carvalho et al., 1993). Multilamellar
vesicles (MLVs) were prepared by drying 1-
palmitoyl-2-arachidonyl-sn-glycero-3-phosphochol-
ine and 1-palmitoyl-2-oleoyl-sn-glycerol in a ratio of
2:1 (n·n-1, in chloroform) under nitrogen. MLVs
were downsized to large unilamellar vesicles by
extrusion (100 nm pore diameter). Final total con-
centration of lipids was 250 mM in 200 mL. Test com-
pounds and 1 mM Ca2+ were added to the vesicles,
and the reaction was started by addition of 500 ng
His-tagged cPLA2 (in 10 mL buffer). After 1 h at 37°C,
1.6 mL MeOH was added, and AA was extracted by
RP-18 solid phase extraction. Following derivatiza-
tion with p-anisidium chloride, the resulting
mixture was analysed by RP-HPLC at 249 nm, as
described by Knospe et al. (1988).
Western blot analysis
The analysis of COX-2, b-actin and cPLA2 was per-
formed in whole cell lysates. The cells were washed
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with cold PBS and lysed for 10 min at 4°C with lysis
buffer [50 mM Tris pH 7.4, 0.5% Nonidet P-40,
0.01% sodium dodecyl sulphate (SDS)] containing
complete protease inhibitor cocktail (Roche, Man-
nheim, Germany). Lysates from adherent cells were
collected by scraping and centrifuged at 12 000¥ g
for 15 min at 4°C.
For analysis of cPLA2 subcellular localization,
J774 cells or peritoneal macrophages were resus-
pended in 50 mM Tris/HCl, pH 7.4, 250 mM
sucrose, 25 mM KCl, 5 mM MgCl2, 1 mM EDTA,
1 mM phenylmethylsulfonyl fluoride, 60 mg·mL-1
soybean trypsin inhibitor and 10 mg·mL-1 leupeptin,
6 h after LPS treatment (J774 cells) or 60 min after
zymosan treatment (peritoneal macrophages) soni-
cated on ice (5 ¥ 10 s), and centrifuged at 100 000¥
g 100 min-1 4°C. The 100 000¥ g supernatant was
referred to soluble fraction (S100); the correspond-
ing pellet was referred to membrane fraction (P100).
Protein concentration in cell lysates was deter-
mined by Bio-Rad Protein Assay (Bio-Rad,
Muenchen, Germany). Equal amounts of protein
(25–35 mg corresponding to 2–4 ¥ 105 cells) were
mixed with gel loading buffer (50 mM Tris, 10%
SDS, 10% glycerol, 10% 2-mercaptoethanol,
2 mg·mL-1 of bromophenol blue) in a ratio of 1:1,
boiled for 3 min and centrifuged at 10 000¥ g for
10 min. Each sample was loaded and analysed by
electrophoresis on a 10% SDS-polyacrylamide gel.
The proteins were transferred on to nitrocellulose
membranes (Hybond ECL Nitrocellulose, Amer-
sham, Rainham, UK). Correct loading of the gel
and transfer of proteins to the nitrocellulose mem-
brane was confirmed by Ponceau S staining. The
membranes were blocked with 0.05% PBS-Tween
containing 3% non-fat dry milk for COX-2; with
0.1% PBS-Tween containing 5% non-fat dry milk
for b-actin and cPLA2. After blocking, the mem-
branes were incubated with the primary antibodies
overnight at 4°C. Rabbit monoclonal anti-COX-2
antibody (Upstate, Lake Placid, NY, USA) was
diluted 1:8000 in 0.05% PBS-Tween, 3% non-fat
dry milk; mouse monoclonal anti-b-actin antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA)
was diluted 1:20 000 in 0.1% PBS-Tween, 5% non-
fat dry milk; rabbit polyclonal anti-cPLA2 antibody
(Santa Cruz Biotechnology) was diluted 1:500 in
0.1% PBS-Tween. After incubation, the membranes
were washed six times with 0.1% PBS-Tween and
incubated for 1.5 h at room temperature with
horseradish peroxidase-conjugated secondary anti-
bodies diluted 1:3000 in 0.1% PBS-Tween contain-
ing 5% non-fat dry milk. The membranes were
washed and protein bands were detected by an
enhanced chemiluminescence system (Amersham
Pharmacia).
Statistical analysis
The results are expressed as mean  standard error
(SEM) of the mean of n observations, where n rep-
resents the number of experiments performed in
different days or the number of animals. Triplicate
wells were used for the various treatment condi-
tions. The IC50 values were calculated by GraphPad
Instat program; data fit was obtained using the sig-
moidal dose–response equation (variable slope)
(GraphPad software) (eicosanoid background release
from unstimulated cells was subtracted from each
experimental point).
The results were analysed by one-way ANOVA fol-
lowed by a Bonferroni post hoc test for multiple
comparisons. A P-value less than 0.05 was consid-
ered significant.
Materials
AA (peroxide free) and MK-886 were obtained from
Cayman Chemical (Inalco, Milan, Italy). The 6-keto
PGF1a antibody was a gift from Prof G. Ciabattoni
(University of Chieti, Italy). [3H-PGE2], [3H-6-keto
PGF1a] and [5,6,8,9,11,12,14,15-3H(N)]AA were from
PerkinElmer Life Sciences (Milan, Italy). Zileuton
was purchased from Sequoia Research Products
(Oxford, UK). EIA kit was from Cayman Chemical
Company. Indomethacin and l-carrageenan type IV
isolated from Gigartina aciculaire and Gigartina pistil-
lata were purchased from Sigma-Aldrich (Milan,
Italy). All other reagents and compounds were
obtained from Sigma-Aldrich.
Stock solutions of zileuton were prepared in
ethanol or in DMSO (for human whole blood assay);
an equivalent amount of ethanol or DMSO was
included in control samples. For animal studies,
zileuton, MK-886 and indomethacin were dissolved
in DMSO and diluted with saline achieving a final
DMSO concentration of 4%. Prior to use as a stimu-
lus, zymosan was suspended in PBS and boiled for
10 min, followed by centrifugation. After resuspen-
sion in PBS, the boiling procedure was repeated
twice more (Gijón et al., 2000).
Results
Effects of zileuton on PGE2 production in
elicited murine peritoneal and in
J774 macrophages
Stimulation of elicited murine peritoneal macroph-
ages with LPS (10 mg·mL-1) plus IFNg (100 U·mL-1)
for 24 h induced a significant (P < 0.001) increase of
PGE2 generation (about 37-fold) compared with
unstimulated cells (control). In the presence of
increasing concentrations of zileuton (1–100 mM), a
significant and concentration-dependent inhibition
BJPEffect of zileuton on prostaglandin biosynthesis
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(P < 0.05 at 1 mM; P < 0.001 at all the other concen-
trations tested) of PGE2 production was observed
(Figure 1A). The calculated IC50 was 5.79 mM (r2 =
0.968). In accordance with its reported efficacy in
various cell-based assays [IC50 = 0.5 to 1 mM] (Carter
et al., 1991), zileuton completely inhibited the elic-
ited formation of cys-LTs at all the concentrations
tested (Figure 1A). The inhibition of PGE2 and cys-
LTs was not related to a toxic effect of the com-
pound, as evaluated by assessment of cell viability
(Figure 1B).
To determine whether the suppression of PG pro-
duction was related to the inhibition of LTs, we
evaluated the effect of zileuton on PGE2 biosynthesis
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Figure 1
Effects of zileuton on prostaglandin production in macrophages and in human whole blood. Zileuton inhibits eicosanoid production in peritoneal
macrophages from 5-lipoxygenase (5-LOX) wild type (WT) (A) and from 5-LOX KO mice (C) activated for 24 h with lipopolysaccharide (LPS)
(10 mg·mL-1) and interferon g (IFNg) (100 U·mL-1) as well as in J774 macrophages (D) and in human whole blood (E) stimulated, for 24 h, with
LPS (10 mg·mL-1). Eicosanoid levels were quantified by radioimmunoassay (PGE2) and enzyme immunoassay [cysteinyl leukotriene (cysLT)] in
medium from cell incubations. Zileuton did not inhibit cell viability in peritoneal macrophages from 5-LOX WT as determined by the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell viability assay (B). Data are expressed as means  SEM from n = 4 independent
experiments performed in triplicate, each. n.d. = not detectable (the level of the eicosanoids was below the detection limit of the respective assay).
***P < 0.001 versus unstimulated cells (C), °P < 0.05; °°°P < 0.001 versus cells activated with LPS + IFNg (peritoneal macrophages) or LPS (J774
macrophages and human whole blood) in the absence of zileuton.
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in activated peritoneal macrophages from 5-LOX
KO mice. These cells do not produce any detectable
amount of LTs. However, as observed with cells from
5-LOX wild type (WT) mice, zileuton inhibited PGE2
formation in a concentration-dependent manner
also in activated peritoneal macrophages from
5-LOX KO mice, although with a slightly higher
IC50 (21.1 mM, r2 = 0.998; Figure 1C). These data
indicate a direct inhibitory effect of zileuton on PG
biosynthesis.
Similar inhibitory effects of zileuton on PGE2
production were observed in the murine macroph-
age cell line J774. Stimulation of J774 macrophages
with LPS (10 mg·mL-1) for 24 h to induce COX-2
expression produced a significant (P < 0.001)
increase of PGE2 compared to unstimulated cells
(control) (Figure 1D). As observed in mouse perito-
neal macrophages, zileuton (1–100 mM) signifi-
cantly (P < 0.05 at 1 mM; P < 0.001 at all the other
concentrations tested) inhibited PGE2 production in
a concentration-dependent manner, with an IC50 of
1.94 mM (r2 = 0.934; Figure 1D).
Effects of zileuton on PGE2 production in
human whole blood and on
carrageenan-induced pleurisy
Next, we evaluated whether zileuton also affected
PG production in a more biologically relevant
system, such as human whole blood stimulated with
LPS (10 mg·mL-1), and in vivo, in a model of acute
inflammation in rats. Importantly, zileuton
(1–100 mM) significantly (P > 0.05 at 1 mM; P < 0.05
at 3.3 mM; P < 0.001 at all the other concentrations
tested) and concentration-dependently inhibited
COX-2-dependent PGE2 production in human
whole blood, with an IC50 of 12.9 mM (r2 = 0.965;
Figure 1E).
In an in vivo model of carrageenan-induced rat
pleurisy, zileuton (at the dose of 10 mg·kg-1, i.p.)
significantly reduced not only the pleural exudate
levels of LTB4 (60%, P < 0.01) (Figure 2A) but also of
PGE2 (47%, P < 0.05) (Figure 2B) as well as the
inflammatory reaction measured as exudate volume
(79%, P < 0.001) (Figure 2C) and number of migrat-
ing cells (39%, P < 0.01) (Figure 2D). A reduced PG
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production, exudate volume and number of inflam-
matory cells were also observed for the COX inhibi-
tor indomethacin (5 mg·kg-1, i.p.) which failed to
significantly suppress LTB4 levels (Figure 2A–D).
Moreover, the PGE2 reduction was not dependent
on the LT inhibition, since MK-886 (1.5 mg·kg-1,
i.p.), which also reduced LTB4 production (75%, P <
0.001), failed to decrease PGE2 levels (Figure 2A,B).
Note that the effect of zileuton in reducing exudate
formation and inflammatory cell migration was
greater than that of MK-886, although MK-886 led
to a greater reduction of LTB4 levels than zileuton,
suggesting that zileuton’s effects were not simply
related to inhibition of LTB4 formation.
Effect of zileuton on mPGES1 and COX-2
The next step was to identify at which level zileuton
inhibited PGE2 production. One possibility to be
considered was that zileuton could inhibit PGE2 for-
mation by interference with mPGES1, which repre-
sents the downstream enzyme involved in PGE2
synthesis, in particular under inflammatory condi-
tions. To this aim, zileuton was tested in a cell-free
assay system using isolated microsomes from IL-1b-
treated A549 cells as the enzyme source (Jakobsson
et al., 1999; Thorén and Jakobsson, 2000). Zileuton
(1–100 mM) did not inhibit mPGES1 activity (con-
version of PGH2 to PGE2) (Figure 3A).
Moreover, zileuton inhibited the generation of
other COX-derived product such as the stable PGI2
metabolite, 6-keto PGF1a. Thus, as for PGE2 produc-
tion, in the presence of increasing concentrations
of zileuton (1–10–100 mM), a significant
concentration-dependent inhibition of stimulated
6-keto PGF1a generation was observed in murine
peritoneal macrophages (IC50 = 2.7 mM; r2 = 0.998)
(Figure 3B). Similar results were obtained in J774
cells (Figure 3C; IC50 = 5.8 mM; r2 = 0.928). A signifi-
cant reduction of 6-keto PGF1a levels by zileuton
(10 mg·kg-1) was also observed in vivo in
carrageenan-induced pleurisy (Figure 3D). These
data suggested that zileuton might influence an
upstream event in PG biosynthesis.
In activated macrophages, COX-2 is the enzyme
responsible for PG production from AA (Brock
et al., 1999; Rossi et al., 2005). However, although
our data point to an interference of zileuton with
COX enzymes, the expression of COX-2 was
neither significantly inhibited by zileuton
(1–100 mM) in mouse peritoneal macrophages acti-
vated with LPS (10 mg·mL-1)/IFNg (100 U·mL-1)
(Figure 4A) nor in J774 cells activated with LPS
(10 mg·mL-1) for 24 h (Figure 4B). Also, zileuton
(1–10–100 mM) did not inhibit the activity of iso-
lated human COX-2 enzyme (Figure 4C). Impor-
tantly, after stimulation of J774 cells with LPS
(10 mg·mL-1) for 24 h (to induce COX-2), followed
by a washout step and 30 min incubation with
exogenous AA (3 and 15 mM, Figure 4D), PGE2 gen-
eration was unaffected by zileuton. Together, these
results exclude mPGES1 or COX-2 expression and
enzymatic activities as possible target of zileuton.
Instead, data showing that zileuton failed to
inhibit PGE2 formation when exogenous AA was
added pointed to a possible action of zileuton at
the level of AA supply.
Effect of zileuton on cPLA2 and AA release
Next, we evaluated the effect of zileuton on the
proximal step of eicosanoid biosynthesis, the release
of AA, which is mediated in macrophages by cPLA2
(Gijón et al., 2000). For this, release of [3H]-AA and
its metabolites from [3H]-AA-labelled J774 macroph-
ages stimulated by LPS (10 mg·mL-1) for 24 h was
assessed. Zileuton (1–100 mM) significantly (P < 0.01
at 1 mM; P < 0.001 at 10 and 100 mM) inhibited the
release of radioactivity in a concentration-
dependent manner (Figure 5A) with an IC50 of
3.5 mM (r2 = 0.994). Pyrrolidine-1, a well-recognized
inhibitor of cPLA2 (Seno et al., 2000), was used as
reference compound. On the other hand, zileuton
(up to 100 mM) neither affected the enzymatic activ-
ity of purified human recombinant cPLA2 in a cell-
free assay (regardless of the nature of the
phospholipid substrate, Figure 5B) nor the expres-
sion (LPS-stimulated macrophages) of cPLA2 (data
not shown).
In intact leukocytes, AA release requires translo-
cation of cPLA2 from the cytosol (S100) to the cel-
lular membranes (P100) (Gijón et al., 1999). We
found that zileuton (10 and 100 mM) almost com-
pletely blocked the translocation of cPLA2 to the
membrane compartment following LPS stimulation
of J744 macrophages (Figure 5C).
In macrophages, cPLA2 is stimulated to release
AA by a wide variety of agents other than LPS, such
as the unphysiological Ca2+-ionophore A23187 and
the physiologically relevant stimulus zymosan
(Gijón et al., 2000). Thus, we evaluated the effect of
zileuton on the AA release in peritoneal macroph-
ages stimulated with calcium ionophore A23187 or
zymosan. Zileuton (1–100 mM) failed to inhibit
radioactivity release (Figure 6A) in peritoneal mac-
rophages stimulated with A23187 (1 mM), whereas it
was effective (P < 0.05 at 1 mM; P < 0.001 at 10 and
100 mM) when the cells were stimulated with
zymosan (30 particles·cell-1) (Figure 6B; IC50 =
8.13 mM; r2 = 0.997). In parallel, we observed a
concentration-dependent inhibition (P > 0.05 at
1 mM; P < 0.05 at 10 mM; P < 0.01 at 100 mM) of PGE2
production (Figure 6C) with an IC50 of 9.85 mM (r2 =
0.966) as well as of cPLA2 translocation to the
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membrane compartment (Figure 6D). Thus, our
data strongly support an inhibitory action of zileu-
ton at the level of AA release mediated by stimuli
such as LPS and zymosan and not by calcium iono-
phore A23187.
Discussion and conclusions
Zileuton is currently approved by the FDA for the
prophylaxis and chronic treatment of asthma in
adults and children older than 12 years. Several
A
75
100
io
n
on
tr
ol
)
0
25
50
P
G
E
2
fo
rm
at
i
(p
er
ce
nt
ag
e 
of
 c
o
B C
0 1 10 100
zileuton (μM)
2.5
5.0
***
°°
°°° P
G
F
1α
(n
g 
m
l-1
)
0.05
0.10
0.15
***
°
°°°
°°°o 
P
G
F
1α
   
   
   
   
   
(n
g 
m
l-1
)
0.0
°°°
6-
ke
to
C        0        1       10      100
zileuton (μM)
plus LPS+IFNγ
0.006-
ke
to
C         0         1       10      100
zileuton (μM)
plus LPS
5.0
g 
ra
t-1
)
D
0.0
2.5
*
#
###
6-
ke
to
 P
G
F
1α
(n
g
vehicle zil indo MK886
carrageenan
Figure 3
Effects of zileuton on microsomal prostaglandin E2 synthase (mPGES1) activity and 6-keto PGF1a production. Zileuton did not significantly inhibit
mPGES1 activity (A). Enzyme activity was determined as described. Zileuton inhibited 6-keto PGF1a production in peritoneal macrophages
activated, for 24 h, with lipopolysaccharide (LPS) (10 mg·mL-1) and interferon g (IFNg) (100 U·mL-1) (B), as well as in J774 macrophages stimulated,
for 24 h, with LPS (10 mg·mL-1) (C), and in carrageenan-induced pleural exudates (D). Prostanoid levels were quantified by radioimmunoassay in
medium from cell incubations and enzyme immunoassay in pleural exudates. Data are expressed as means  SEM from n = 4 independent
experiments performed in triplicate, each. ***P < 0.001 versus unstimulated cells (C), °P < 0.05; °°P < 0.01; °°°P < 0.001 versus cells activated in
the absence of zileuton with LPS + IFNg (peritoneal macrophages) or LPS (J774 macrophages); #P < 0.05; ###P < 0.001 versus in the presence
of vehicle (carrageenan-induced pleurisy).
BJPEffect of zileuton on prostaglandin biosynthesis
British Journal of Pharmacology (2010) 161 555–570 563
studies indicate that zileuton is a specific inhibitor
of 5-LOX, resulting in the suppression of LT produc-
tion (Berger et al., 2007). In this study, we found
that, besides inhibition of LTs, zileuton also pro-
duced a significant decrease of PG production in
vitro (thioglycolate-elicited mouse peritoneal mac-
rophages activated with LPS/IFNg or zymosan and
murine J774 macrophages activated with LPS), as
well as in a biologically relevant test system, i.e.
human whole blood, and in vivo (carrageenan-
induced pleurisy). Also, we identified the release of
AA by cPLA2 as the possible target of zileuton
action.
Zileuton is the only commercially available
inhibitor of 5-LOX (Zyflo®). In clinical trials, it has
been shown to induce acute bronchodilator effects,
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likely related to inhibition of cysLTs and their action
on bronchial smooth muscle tone. However, zileu-
ton also provides a chronic improvement of airway
functions, associated with a reduction of inflamma-
tory components of asthma, such as oedema, cellular
infiltration and mucus production (Drazen et al.,
1999), and decreases the dose of anti-inflammatory
glucocorticoids required to control asthma. Notably,
although doses of zileuton of 400 and 600 mg
were equally effective for acute improvement of
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pulmonary functions, a significant improvement of
chronic airway function was observed only after four
times daily administration of 600 mg compound
(Liu et al., 1996). Therefore, the recommended oral
dosage of zileuton for treatment of asthma is 4 ¥
600 mg·day-1 (or 2 ¥ 1200 mg·day-1 for the recently
approved extended release tablets, Zyflo CR®), for a
total daily dose of 2400 mg, resulting in plasma peak
levels of about 5 mg·mL-1 (corresponding to about
21 mM) and systemic exposure (mean area under
curve) of 19.2 mg·h·mL-1. Although a 93% binding to
plasma proteins has to be taken into account, these
plasma concentrations clearly exceed the IC50 values
for 5-LOX in the blood (i.e. 0.5 to 1 mM), and the
contribution of effects on other targets to the overall
action of zileuton is a reasonable possibility.
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Here, we show that zileuton inhibits PG produc-
tion in vitro (mouse peritoneal macrophages, J774
macrophages, human whole blood) as well as in vivo
(carrageenan-induced pleurisy in rats). In particular,
the observed IC50 for inhibition of PGE2 in LPS-
stimulated whole blood was around 13 mM. Thus,
although the IC50 value for PG biosynthesis is higher
in comparison to those reported for 5-LOX, it clearly
reflects pharmacologically achievable concentra-
tions by the standard doses of zileuton (plasma peak
level of 21 mM) (Dube et al., 1998) despite 93%
binding to plasma proteins.
The possible implications of these findings in
patients undergoing asthma therapy with zileuton
and if inhibition of PGs may (or may not) partially
account for the chronic improvement of airway
inflammation (oedema, cellular infiltration)
observed in these patients remain to be determined
during clinical treatment. In fact, it remains to be
established if the concentration achieved by the rec-
ommended oral doses of zileuton for treatment of
asthma effectively inhibits PG production in
patients, by, for instance, measuring urinary excre-
tion of PGs and PG metabolites. In this regard, it has
to be noted that a decreased amount of prostanoids
has been observed in the bronchoalveolar lavage
fluid of antigen-challenged ragweed-allergic human
subjects treated with standard doses of zileuton
(Kane et al., 1995).
We observed a reduction of PGE2 levels of about
50% in the pleural exudates of carrageenan-treated
rats by i.p. treatment with zileuton (10 mg·kg-1). A
similar inhibition was found for LTB4 (~60%) and
the treatment with the compound significantly
attenuated the inflammatory reaction, measured as
exudate volume and number of infiltrating cells.
Notably, i.p. treatment with 1.5 mg·kg-1 MK-886 (an
inhibitor of the 5-LOX activating protein), which
also resulted in a stronger inhibition of LTB4 levels
than zileuton (~75%), did not influence PG produc-
tion and had only moderate effects on plasma exu-
dation and cellular infiltration. Therefore, it
appeared likely that the anti-inflammatory effects of
zileuton are not only restricted to reduction of LT
formation but might partially also depend on inhi-
bition of prostanoids. For instance, the COX inhibi-
tor indomethacin, which instead suppressed pleural
PGE2 levels without affecting LTB4, efficiently
reduced exudate volume and cell number.
An inhibitory effect of zileuton on the levels of
prostanoids has been previously observed in certain
in vivo experimental models. In particular, it has
been shown that Zyflo® reduced PGE2 concentra-
tions in liver metastases of N-nitrosobis-2-
oxopropylamine-induced pancreatic carcinoma in
Syrian Golden hamsters (Gregor et al., 2005) and
decreased PGE2 levels in rat oesophageal adenocar-
cinoma (Chen et al., 2004). However, the in vitro and
in vivo effects of zileuton reported in the literature
are conflicting (Berger et al., 2007) and these obser-
vations have neither been explained nor further
explored.
Here, we have investigated the biochemical
mechanism of the inhibitory effect of zileuton on
PG production in vitro. According to previous results
(Rossi et al., 2005), one of the possible mechanism/s
could be related to the positive modulation of LTs
on PG production. Thus, suppression of LT forma-
tion by zileuton would result in a consequent inhi-
bition of prostanoid biosynthesis. However, this
mechanism may only partially account for inhibi-
tion of PG production by zileuton. This was sup-
ported by the following findings: (i) significant
inhibition of PGs was observed at concentrations of
zileuton higher than those required for a complete
suppression of 5-LOX activity; (ii) as observed in
peritoneal macrophages from 5-LOX WT mice acti-
vated with LPS/IFNg, zileuton inhibited PGE2 pro-
duction also in cells from 5-LOX KO mice, although
with a slightly higher IC50; (iii) zileuton inhibited
PG production also in J774 macrophages which do
not produce detectable amount of LT following
stimulation with LPS; (iv) MK-886 (1.5 mg·kg-1, i.p.),
which also reduced the in vivo production of LTB4,
failed to decrease PG levels. Thus, the inhibition of
prostanoid biosynthesis by zileuton might only par-
tially depend on suppression of LTs (and therefore
on a decreased LT action on the COX pathway) and
seems to be rather related to a direct action at the
level of one of the steps of the AA cascade leading to
PG biosynthesis.
During an inflammatory insult, PLA2 releases AA
from cell membrane phospholipids, which is subse-
quently metabolized through a series of enzymatic
reactions to yield biologically active mediators.
COX enzymes convert AA into PGH2, which is
further metabolized by terminal PG synthases to
PGE2, 6-keto PGF1a, PGD2, PGF2a and thromboxane
A2. Since mPGES1 is an efficient downstream
enzyme for the production of PGE2 in LPS-activated
macrophages (Lazarus et al., 2002), zileuton might
target mPGES1 and consequently inhibit PGE2 for-
mation. Our results (inhibition of 6-keto PGF1a by
zileuton in LPS/IFNg activated peritoneal macroph-
ages and LPS-activated J774 macrophages as well as
the failure of zileuton to inhibit mPGES1 activity in
a cell-free assay) demonstrated that the action of
zileuton on PGE2 production occurred through a
different mechanism. In addition, interference with
COX-2, the main COX isoform responsible for pros-
tanoid production in LPS/IFNg-stimulated perito-
neal macrophages and in LPS-stimulated J774
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macrophages (Brock et al., 1999), can be excluded,
since zileuton neither affected COX-2 expression
nor its activity in a cell-free assay. Hence, a possible
point of attack of zileuton could be the release of
AA, which represents the initial and rate-limiting
step in eicosanoid biosynthesis. This hypothesis was
supported by the fact that zileuton failed to inhibit
PG formation in the presence of exogenous AA and
was finally confirmed by the finding that zileuton
inhibited the release of AA from macrophages
induced by LPS or zymosan. Importantly, the IC50
observed for inhibition of AA release in LPS-
stimulated J774 macrophages (3.5 mM) is consistent
with those observed for inhibition of PGE2
(1.94 mM) or 6-keto PGF1a (5.8 mM).
The inhibitory action of zileuton on the release
of AA from membrane phospholipids was not
related to a direct effect on cPLA2 activity (as
assessed in a cell-free assay of purified human
recombinant cPLA2) but seemed to depend on the
inhibition of cPLA2 translocation to the membranes,
a movement crucial for the cellular activation of the
enzyme (Gijón and Leslie, 1999). It is well known
that increases in the intracellular Ca2+ concentration
and phosphorylation by mitogen-activated protein
kinases are involved in cPLA2 activation in mac-
rophages (Gijón et al., 2000). Interestingly, zileuton
prevented AA release when physiopathologically
relevant stimuli were used (LPS or zymosan), but no
significant effects were observed when the Ca2+-
ionophore A23187 was utilized. These data suggest
an interference with a mechanism independent of
Ca2+ and suggest further evaluation of other relevant
stimulatory conditions. Notably, many of the data
concerning the selective inhibition of 5-LOX by
zileuton result from the use of calcium ionophore
A23187 as stimulus for eicosanoid production
(Carter et al., 1991; Bell et al., 1992) and the effect
on AA release and prostanoid biosynthesis might
have been overcome. However, further investiga-
tions are needed to elucidate the precise mechanism
of the action of zileuton.
The finding that zileuton inhibits AA release has
several important implications. First, the overall
inhibition of 5-LOX products by zileuton seems to
be due, at least in our experimental models, to two
different mechanisms: (i) the well known direct
effect on 5-LOX activity, and (ii) the reduction of AA
availability. Second, suppression of PG production
by zileuton has to be carefully taken into account
when considering its action in experimental models
of inflammation. Third, in cell types metabolizing
AA to other products than LTs and PGs (i.e. cyto-
chrome P450 monooxygenase pathways) (Specto,
2009), zileuton might also affect their formation
with additional important implications.
In the light of these considerations, the effect on
PG production should be considered when the drug
is utilized as a pharmacological tool to evaluate the
role of LTs. For example, the role of 5-LOX metabo-
lites in carcinogenesis (Chen et al., 2006) has been
addressed using zileuton and it has been demon-
strated that it exerts beneficial effect in several
experimental in vivo models of cancer (Gregor et al.,
2005; Li et al., 2005). Since the important role of PG
in tumour initiation and progression is well known,
the effects responsible for the positive action of
zileuton should be carefully reassessed.
In conclusion, our results demonstrate that zileu-
ton inhibits PG production by interfering at the
level of AA release and suggest that its mechanism of
action as well as its use as pharmacological tool in
different experimental models of inflammation
should be re-evaluated.
Acknowledgements
The authors thank the Italian MIUR and Deutsche
Forschungsgemeinschaft for financial support. C.P.
received a Carl-Zeiss stipend.
Conflicts of interest
None.
References
Alexander SPH, Mathie A, Peters JA (2009). Guide to
Receptors and Channels (GRAC), 4th edn. Br J
Pharmacol 158 (Suppl. 1): S1–S254.
Beierschmitt WP, McNeish JD, Griffiths RJ, Nagahisa A,
Nakane M, Amacher DE (2001). Induction of hepatic
microsomal drug-metabolizing enzymes by inhibitors of
5-lipoxygenase (5-LO): studies in rats and 5-LO
knockout mice. Toxicol Sci 63: 15–21.
Bell RL, Young PR, Albert D, Lanni C, Summers JB,
Brooks DW et al. (1992). The discovery and
development of zileuton: an orally active 5-lipoxygenase
inhibitor. Int J Immunopharmacol 14: 505–510.
Berger W, De Chandt MT, Cairns CB (2007). Zileuton:
clinical implications of 5-lipoxygenase inhibition in
severe airway disease. Int J Clin Pract 61: 663–676.
Bradford MM (1976). A rapid and sensitive method for
the quantitation of microgram quantities of protein
utilizing the principle of protein-dye binding. Anal
Biochem 72: 248–254.
Brock TG, McNish RW, Peters-Golden M (1999).
Arachidonic acid is preferentially metabolized by
cyclooxygenase-2 to prostacyclin and prostaglandin E2. J
Biol Chem 274: 11660–11666.
BJP A Rossi et al.
568 British Journal of Pharmacology (2010) 161 555–570
Carter GW, Young PR, Albert DH, Bouska J, Dyer R,
Bell RL et al. (1991). 5-lipoxygenase inhibitory activity
of zileuton. J Pharmacol Exp Ther 256: 929–937.
de Carvalho MS, McCormack FX, Leslie CC (1993). The
85-kDa, arachidonic acid-specific phospholipase A2 is
expressed as an activated phosphoprotein in Sf9 cells.
Arch Biochem Biophys 306: 534–540.
Chen X, Wang S, Wu N, Sood S, Wang P, Jin Z et al.
(2004). Overexpression of 5-lipoxygenase in rat and
human esophageal adenocarcinoma and inhibitory
effects of zileuton and celecoxib on carcinogenesis.
Cancer Res 10: 6703–6709.
Chen X, Sood S, Yang CS, Li N, Sun Z (2006).
Five-lipoxygenase pathway of arachidonic acid
metabolism in carcino-genesis and cancer
chemoprevention. Curr Cancer Drug Targets 6: 613–622.
Collin M, Rossi A, Cuzzocrea S, Patel NS, Di Paola R,
Hadley J et al. (2004). Reduction of the multiple organ
injury and dysfunction caused by endotoxemia in
5-lipoxygenase knockout mice and by the
5-lipoxygenase inhibitor zileuton. J Leukoc Biol 76:
961–970.
Cuzzocrea S, Rossi A, Mazzon E, Di Paola R, Genovese T,
Muià C et al. (2005). 5-Lipoxygenase modulates colitis
through the regulation of adhesion molecule expression
and neutrophil migration. Lab Invest 85: 808–822.
Drazen JM, Israel E, O’Byrne PM (1999). Treatment of
asthma with drugs modifying the leukotriene pathway.
N Engl J Med 340: 197–206.
Dube LM, Swanson L, Awani WM, Bell RL, Carter GW
(1998). Zileuton: the first leukotriene synthesis inhibitor
for use in the management of chronic asthma. In:
Drazen JM, Dahlen SE, Lee TH (eds). Lung Biology in
Health and Disease. Marcel Dekker: New York, 391 pp.
Genovese T, Rossi A, Mazzon E, Di Paola R, Muià C,
Caminiti R et al. (2008). Effects of zileuton and
montelukast in mouse experimental spinal cord injury.
Br J Pharmacol 153: 568–582.
Gijón MA, Leslie CC (1999). Regulation of arachidonic
acid release and cytosolic phospholipase A2 activation. J
Leukoc Biol 65: 330–336.
Gijón MA, Spencer DM, Kaiser AL, Leslie CC (1999).
Role of phosphorylation sites and the C2 domain in
regulation of cytosolic phospholipase A2. J Cell Biol 145:
1219–1232.
Gijón MA, Spencer DM, Siddiqi AR, Bonventre JV,
Leslie CC (2000). Cytosolic phospholipase A2 is required
for macrophage arachidonic acid release by agonists that
Do and Do not mobilize calcium. Novel role of
mitogen-activated protein kinase pathways in cytosolic
phospholipase A2 regulation. J Biol Chem 275:
20146–20156.
Gregor JI, Kilian M, Heukamp I, Kiewert C,
Kristiansen G, Schimke I et al. (2005). Effects of selective
COX-2 and 5-LOX inhibition on prostaglandin and
leukotriene synthesis in ductal pancreatic cancer in
Syrian hamster. Prostaglandins Leukot Essent Fatty Acids
73: 89–97.
Hamad AM, Sutcliffe AM, Knox AJ (2004).
Aspirin-induced asthma: clinical aspects, pathogenesis
and management. Drugs 64: 2417–2432.
Jakobsson PJ, Thorén S, Morgenstern R, Samuelsson B
(1999). Identification of human prostaglandin E
synthase: a microsomal, glutathione-dependent,
inducible enzyme, constituting a potential novel drug
target. Proc Natl Acad Sci U S A 96: 7220–7225.
Kane GC, Tollino M, Pollice M, Kimm CJ, Cohn J,
Murray JJ et al. (1995). Insights into IgE-mediated lung
inflammation derived from a study employing a
5-lipoxygenase inhibitor. Prostaglandins 50: 1–18.
Knospe J, Steinhilber D, Herrmann T, Roth HJ (1988).
Picomole determination of 2,4-dimethoxyanilides of
prostaglandins by high-performance liquid
chromatography with electrochemical detection. J
Chromatogr 442: 444–450.
Kwak HJ, Park KM, Choi HE, Lim HJ, Parkm JH, Park HY
(2010). The cardioprotective effects of zileuton, a
5-lipoxygenase inhibitor, are mediated by COX-2 via
activation of PKCdelta. Cell Signal 22: 80–87.
Lazarus M, Kubata BK, Eguchi N, Fujitani Y, Urade Y,
Hayaishi O (2002). Biochemical characterization of
mouse microsomal prostaglandin E synthase-1 and its
colocalization with cyclooxygenase-2 in peritoneal
macrophages. Arch Biochem Biophys 397: 336–341.
Li N, Sood S, Wang S, Fang M, Wang P, Sun Z et al.
(2005). Overexpression of 5-lipoxygenase and
cyclooxygenase 2 in hamster and human oral cancer
and chemopreventive effects of zileuton and celecoxib.
Clin Cancer Res 11: 2089–2096.
Liu MC, Dubé LM, Lancaster J (1996). Acute and
chronic effects of a 5-lipoxygenase inhibitor in asthma:
a 6-month randomized multicenter trial. Zileuton Study
Group. J Allergy Clin Immunol 98: 859–871.
Mosmann T (1983). Rapid colorimetric assay for cellular
growth and survival: application to proliferation and
cytotoxicity assay. J Immunol Methods 65: 55–63.
Nunoshiba T, deRojas-Walker T, Wishnok JS,
Tannenbaum SR, Demple B (1993). Activation by nitric
oxide of an oxidative-stress response that defends
Escherichia coli against activated macrophages. Proc Natl
Acad Sci U S A 90: 9993–9997.
Peters-Golden M, Brock TG (2000). Intracellular
compartmentalization of leukotriene biosynthesis. Am J
Respir Crit Care Med 161: S36–S40.
Peters-Golden M, Henderson WR Jr (2007).
Leukotrienes. N Engl J Med 357: 1841–1854.
Rossi A, Acquaviva AM, Iuliano F, Di Paola R,
Cuzzocrea S, Sautebin L (2005). Up-regulation of
prostaglandin biosynthesis by leukotriene C4 in elicited
mice peritoneal macrophages activated with
lipopolysaccharide/interferong. J Leukoc Biol 78:
985–991.
BJPEffect of zileuton on prostaglandin biosynthesis
British Journal of Pharmacology (2010) 161 555–570 569
Sautebin L, Ianaro A, Rombola L, Ialenti A, Sala A,
Di Rosa M (1999). Cyclooxygenase-2-dependent
generation of 8-epiprostaglandin F2a by
lipopolysaccharide-activated J774 macrophages. Inflamm
Res 48: 503–508.
Seno K, Okuno T, Nishi K, Murakami Y, Watanabe F,
Matsuura T et al. (2000). Pyrrolidine inhibitors of
human cytosolic phospholipase A(2). J Med Chem 43:
1041–1044.
Siemoneit U, Hofmann B, Kather N, Lamkemeyer T,
Madlung J, Franke L et al. (2008). Identification and
functional analysis of cyclooxygenase-1 as a molecular
target of boswellic acids. Biochem Pharmacol 75:
503–513.
Specto AA (2009). Arachidonic acid cytochrome P450
epoxygenase pathway. J Lipid Res 50: 52–56.
Tacconelli S, Capone M, Sciulli M, Ricciotti E,
Patrignani P (2002). The biochemical selectivity of novel
COX-2 inhibitors in whole blood assays of
COX-isozyme activity. Curr Med Res Opin 18: 503–511.
Thorén S, Jakobsson PJ (2000). Coordinate up- and
down-regulation of glutathione-dependent
prostaglandin E synthase and cyclooxygenase-2 in A549
cells. Inhibition by NS-398 and leukotriene C4. Eur J
Biochem 267: 6428–6434.
BJP A Rossi et al.
570 British Journal of Pharmacology (2010) 161 555–570
